RF 1010

Drug Profile

RF 1010

Latest Information Update: 19 Jan 2011

Price : $50

At a glance

  • Originator SuperGen
  • Class Antianaemics; Growth factors
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaemia; Neutropenia

Most Recent Events

  • 19 Jan 2011 Discontinued - Phase-II for Anaemia in USA (unspecified route)
  • 19 Jan 2011 Discontinued - Phase-II for Neutropenia in USA (unspecified route)
  • 03 Aug 2001 RF 1010 is available for licensing http://www.supergen.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top